Shuanglu Pharmaceutical announced that revenue for the first half of 2026 was 251 million yuan, down 17.51% year on year; net profit loss attributable to shareholders of listed companies was 255 million yuan, which was 121 million yuan in the first half of 2025, which changed from profit to loss year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 37.499 million yuan, a year-on-year decrease of 85.58%. On February 11, 2026, the company reported a case involving a former financial officer suspected of infringing on the company's interests. On March 10, the company received a notice of filing the case, which is still under investigation.

Shuanglu Pharmaceutical announced that revenue for the first half of 2026 was 251 million yuan, down 17.51% year on year; net profit loss attributable to shareholders of listed companies was 255 million yuan, which was 121 million yuan in the first half of 2025, which changed from profit to loss year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 37.499 million yuan, a year-on-year decrease of 85.58%. On February 11, 2026, the company reported a case involving a former financial officer suspected of infringing on the company's interests. On March 10, the company received a notice of filing the case, which is still under investigation.